申请人:Array BioPharma Inc.
公开号:US20150299182A1
公开(公告)日:2015-10-22
The present invention relates to crystalline polymorph forms of (1S)-1-[5-(3-[(2-methylpyridin-3-yl)oxy]-5-(pyridin-2-ylsulfanyl)pyridin-2-yl}amino)-1,2,4-thiadiazol-3-yl]ethane-1,2-diol, to pharmaceutical compositions comprising such crystalline polymorph forms, and to processes for preparing them. The invention further relates to methods of treatment of diabetes related disorders comprising administering such solid-state forms or compositions thereof to a subject, and to use of such crystalline polymorph forms in the manufacture of medicaments.
本发明涉及(1S)-1-[5-(3-[(2-甲基吡啶-3-基)氧基]-5-(吡啶-2-基硫基)吡啶-2-基}氨基)-1,2,4-噻二唑-3-基]乙烷-1,2-二醇的晶体多形形式,以及包含这种晶体多形形式的制药组合物,以及制备它们的方法。本发明还涉及将这种固态形式或其组合物用于治疗与糖尿病相关的疾病的方法,以及使用这种晶体多形形式制造药物。